Low-dose lenvatinib and anti-programmed cell death protein-1 combination therapy in patients with heavily pre-treated recurrent ovarian and endometrial cancer: a pilot study.

Xiao ShangHao SuXin ChenYutong WangXirun WanYing ZhangYing JinFengzhi Feng

Published in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2024)

Low-dose lenvatinib in combination with anti-PD-1 therapy showed promising efficacy and favorable tolerability in patients with heavily pre-treated ovarian and endometrial cancer.

Keyphrases

endometrial cancer
low dose
combination therapy
high dose
open label
stem cells
binding protein
study protocol
bone marrow